Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Chemotherapeutic medicinal products
In pharmacokinetic studies, EMEND, when given as a regimen of 125 mg on Day 1 and 80 mg/day on
Days 2 and 3, did not influence the pharmacokinetics of docetaxel administered intravenously on
Day 1 or vinorelbine administered intravenously on Day 1 or Day 8. Because the effect of EMEND on
the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of EMEND
on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally
administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g.,
etoposide, vinorelbine) cannot be excluded. Caution is advised and additional monitoring may be
appropriate in patients receiving medicinal products metabolised primarily or partly by CYP3A4 (see
section 4.4). Postmarketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have
been reported after aprepitant and ifosfamide co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
22
Day 1 or vinorelbine administered intravenously on Day 1 or Day 8. Because the effect of EMEND on
the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of EMEND
on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally
administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g.,
etoposide, vinorelbine) cannot be excluded. Caution is advised and additional monitoring may be
appropriate in patients receiving medicinal products metabolised primarily or partly by CYP3A4 (see
section 4.4). Postmarketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have
been reported after aprepitant and ifosfamide co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Chemotherapeutic medicinal products
Interaction studies with fosaprepitant 150 mg and chemotherapeutic medicinal products have not been
conducted; however, based on studies with oral aprepitant and docetaxel and vinorelbine, IVEMEND
150 mg is not expected to have a clinically relevant interaction with intravenously administered
docetaxel and vinorelbine. An interaction with orally administered chemotherapeutic medicinal
products metabolised primarily or partly by CYP3A4 (e.g., etoposide, vinorelbine) cannot be
excluded. Caution is advised and additional monitoring may be appropriate in patients receiving
medicinal products metabolised primarily or partly by CYP3A4 (see section 4.4). Postmarketing
events of neurotoxicity, a potential adverse reaction of ifosfamide, have been reported after aprepitant
and ifosfamide co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage b78fc24de0358af2b4584638fa3e208590245fef03e4d180698051baf33c81fe · Zeichen 2891–3735 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.